1-855-378-42281-855-378-4228
One of the outpatient rehabilitation options for individuals in Ravendale who are struggling with opioid dependence and addiction is called opioid maintenance therapy. Licensed centers and doctors are authorized to give specific meds to opioid dependent individuals, many that are opioid-based also and are addiction. With low amounts the individual doesn't experience high feelings but also doesn't have intense cravings and is not experiencing opioid withdrawal. Methadone is the first med administered for this purpose, but there are other choices currently to select from.
Methadone is an opiate and is meant to be taken at an out-patient medical center certified to administer the drug, which is taken daily in liquid or pill form. The cost of the drug is approximately $150 monthly. Buprenorphine is also an opioid based med, and is a pill often taken every other day. But different from Methadone that is only be administered in well-regulated medical centers, Buprenorphine can be prescribed and dispensed in doctor's offices. The monthly cost of buprenorphine is around $300.00 per month for the generic version of the med. There is also a version of buprenorphine that contains the ingredient naloxone, which is a drug which reverses the effects of opioids. Someone taking this version of the drug, also known as Suboxone, would find it more difficult to get high from opioids if they relapsed while taking the drug. It too is taken on a daily basis, and costs approximately $450 per month. Naltrexone is an additional drug used in opioid maintenance therapy, but unlike the other medications aforementioned it's an opiate blocker and isn't an opioid. A person has the choice to take this drug as a monthly shot, which is called Vivitrol. As an opioid blocker, it prevents an individual from experience being high from opioids, and therefore lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 monthly.
For All Drug and Alcohol Rehab Programs In Ravendale, Click Here.
